Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Go back to Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 21.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.62 | 52 Week High | $42.49 | |||
| Open | $21.62 | 52 Week Low | $16.64 | |||
| Day High | $21.62 | P/E | N/A | |||
| Day Low | $21.62 | EPS | $-0.42 | |||
| Volume | 1,289 | |||||
